Steven J. Quimby

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

Linda M. Rorick‐Kehn, Jeffrey M. Witkin, Michael A. Statnick et al. · Neuropharmacology · 2013 · 148 citations

Psychoactive Drug, Psychiatry, Functional Selectivity +7

Synthesis and Evaluation of¹¹C-LY2795050 as a κ-Opioid Receptor Antagonist Radiotracer for PET Imaging

Ming‐Qiang Zheng, Nabeel Nabulsi, Su Kim et al. · Journal of Nuclear Medicine · 2013 · 90 citations · Full text

Discovery of Aminobenzyloxyarylamides as κ Opioid Receptor Selective Antagonists: Application to Preclinical Development of a κ Opioid Receptor Antagonist Receptor Occupancy Tracer

Charles H. Mitch, Steven J. Quimby, Concepción Pedregal et al. · Journal of Medicinal Chemistry · 2011 · 82 citations · Full text

Molecular Pharmacology, Receptor Occupancy Tracers, Preclinical Development +15

Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1

Katherine M. Partridge, Stephen Antonysamy, Shobha Bhattachar et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 27 citations · Full text

Medicinal Chemistry, Chemoprevention Strategy, Biochemistry +8

Characterization of 3,3-dimethyl substituted N-aryl piperidines as potent microsomal prostaglandin E synthase-1 inhibitors

Steven L. Kuklish, Stephen Antonysamy, Shobha Bhattachar et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 26 citations · Full text

Medicinal Chemistry, Pharmaceutical Science, Biochemistry +8